Wennink, R.A.W., Ayuso, V.K., De Vries, L.A., et al. (2021) Tocilizumab as an Effective Treatment Option in Children with Refractory Intermediate and Panuveitis. Ocular Immunology and Inflammation, 29, 21-25.
https://doi.org/10.1080/09273948.2020.1712431

has been cited by the following article:

• TITLE: Progress in the Use of Glucocorticoids and Biological Agents in Non-Infectious Uveitis

  AUTHORS: Yuxuan Liu, Xunyu Zou, Shizhou Cheng, Zuhai Zhang

  KEYWORDS: Non-Infectious Uveitis, Glucocorticoids, Biological Agents

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.2, February 7, 2024

  ABSTRACT: One of the main immune-mediated diseases that lead to avoidable blindness is non-infectious uveitis. Glucocorticoids are the first-line therapy choice for noninfectious uveitis; however, biologics are also showing promise in the management of this condition. The description of glucocorticoid and biologic usage in non-infectious uveitis is the main topic of this paper.